Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

NG Biotech

NG Biotech develops and manufactures novel in vitro diagnostic tools for therapy monitoring at the point of care (ons... read more Featured Products: More products

Download Mobile App




Rapid Test Promises Faster Answers for Drug-Resistant Infections

By LabMedica International staff writers
Posted on 19 Feb 2026

Drug-resistant pathogens continue to pose a growing threat in healthcare facilities, where delayed detection can impede outbreak control and increase mortality. More...

Candida auris is notoriously difficult to identify and has been linked to hospital-wide outbreaks, while carbapenem-resistant Acinetobacter baumannii can spread rapidly in clinical settings.

A new pair of rapid lateral-flow assays has now received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA), enabling 15-minute identification of Candida auris and differentiation of key carbapenemases in Acinetobacter to support faster infection control and treatment decisions.

NG Biotech (Guipry, France), in partnership with Hardy Diagnostics (Santa Maria, CA, USA), announced Breakthrough Device designation for NG-TEST Candida auris and NG-TEST Acineto-5. Both assays target pathogens classified as critical by the World Health Organization (WHO). Developed and manufactured in France by NG Biotech and distributed exclusively in the United States by Hardy Diagnostics, the tests are currently available for research use only while U.S. regulatory review continues.

NG-TEST Candida auris is the first lateral-flow immunoassay specifically designed to identify C. auris from cultured specimens within 15 minutes. Published data cited in the announcement report 100% agreement with reference methods across diverse isolates. These attributes position the assay for use in outbreak investigations and infection control programs where rapid confirmation from cultures is required.

NG-TEST Acineto-5 detects and differentiates five major carbapenemase families—OXA‑23‑like, OXA‑24/143‑like, OXA‑58‑like, VIM, and NDM—directly from Acinetobacter samples, delivering results within 15 minutes. The assay is PCR-free and designed for straightforward use without specialized equipment. Carbapenem-resistant A. baumannii, listed by the World Health Organization among priority bacterial pathogens, poses a high risk in hospitals due to its resistance profile and rapid transmission.

By accelerating detection of high‑risk pathogens, the assays are intended to enhance surveillance and guide infection control decisions while broader regulatory evaluation proceeds. The companies emphasize the role of rapid results in supporting global efforts against antimicrobial resistance.

"These breakthrough designations validate both the technology behind our assays and the real-world need they address," said Milovan Stankov-Pugès, CEO, NG Biotech.

"The designation underscores the growing urgency around rapid detection of multidrug-resistant organisms that pose serious risks in healthcare settings," said Andre Hsiung, Chief Scientific Officer of Hardy Diagnostics.

Related Links
NG Biotech
Hardy Diagnostics


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.